Fractyl Health (GUTS) Fundamental Analysis: Revenue, Earnings & Valuation

9.59 / 10

Outperform

Fundamentals score 9.6/10, with strong Profit‑MV, Cash‑UP and cash‑MV metrics. Asset‑MV and cost‑of‑sales also positive. Weaknesses appear in PB‑ROE and current‑asset turnover. Overall fundamental rating is Outperform with a 9.59 composite score.

Analysis Checks(7/10)

Profit-MV

Value0.41

Score2/3

Weight2.31%

1M Return0.17%

Net income-Revenue

Value-0.16

Score2/3

Weight-2.97%

1M Return-0.22%

PB-ROE

Value-0.23

Score0/3

Weight-65.37%

1M Return-6.09%

Current assets turnover ratio

Value0.00

Score1/3

Weight-3.73%

1M Return-0.27%

Cash-UP

Value-0.01

Score3/3

Weight41.86%

1M Return2.87%

Total assets turnover ratio

Value0.00

Score2/3

Weight20.04%

1M Return1.43%

Cost of sales ratio (%)

Value70.30

Score3/3

Weight25.51%

1M Return1.95%

Asset-MV

Value-0.48

Score3/3

Weight104.95%

1M Return6.94%

Inventory turnover days

Value230.09

Score1/3

Weight-32.57%

1M Return-2.65%

Cash-MV

Value-0.09

Score2/3

Weight9.97%

1M Return0.79%

Is GUTS fundamentally strong?

GUTS scores 9.59/10 on fundamentals and holds a Discounted valuation at present. Backed by its -744.17% ROE, 0.00% net margin, -0.56 P/E ratio, 8.39 P/B ratio, and -14.81% earnings growth, these metrics solidify its Outperform investment rating.